Sort
10,766 grants matching “checkpoint inhibitor”
Mechanism of Mitotic Checkpoint in Mammalian Cells
$125,322Timothy Yen · Research Inst Of Fox Chase Can Ctr · R01 · FY2010 · GM
Pilot Trial of Nivolumab plus Cabozantinib for Advanced Solid Tumors in Patients with HIV infection
$125,216Edward Chu · Albert Einstein College Of Medicine · P30 · FY2020 · CA
Mechanisms of UV-induced DNA damage responses and carcinogenesis in skin
$125,140Paul Nghiem · University Of Washington · R01 · FY2019 · AR
CCSG Supplement: ATR Inhibition in Advanced PD(L)1-Refractory Merkel Cell Carcinoma
$125,000Thomas James Lynch · Fred Hutchinson Cancer Center · P30 · FY2023 · CA
Characterization of the metastatic TIME by subcellular spatial profiling
$125,000Diego A Pedroza · Baylor College Of Medicine · K99 · FY2025 · GM
Characterization of the metastatic TIME by subcellular spatial profiling
$125,000Diego A Pedroza · Baylor College Of Medicine · K99 · FY2024 · GM
Administrative Supplement P30 Cancer Center Support Grant (CCSG): Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy
$125,000Eric R. Fearon · University Of Michigan At Ann Arbor · P30 · FY2025 · CA
Eukaryotic Nuclear Functions: from Nucleosomes to Chromosomes
$125,000Paul D. Kaufman · Univ Of Massachusetts Med Sch Worcester · R35 · FY2020 · GM
Case Comprehensive Cancer Center Support Grant
$124,938Stanton L Gerson · Case Western Reserve University · P30 · FY2022 · CA
CONTROL OF INITIATION OF DNA REPLICATION IN LUNG CANCER
$124,850Eastern Virginia Medical School · R01 · FY2005 · CA
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
$124,568Dilip Thomas · Stanford University · K99 · FY2024 · HL
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
$124,568Dilip Thomas · Stanford University · K99 · FY2023 · HL
Dissecting mechanisms of immunotherapy resistance in melanoma patients
$124,559Benjamin Izar · Columbia University Health Sciences · K08 · FY2021 · CA
Enhancing TIL efficacy in NSCLC through epigenetic reprogramming and computational modeling
$124,546Daniel Ray Plaugher · University Of Kentucky · K99 · FY2025 · CA
Request for Supplemental Funds aligned to CA160495
$124,464Andrew E Aplin · Thomas Jefferson University · R01 · FY2019 · CA
Translational Research and Interventional Oncology Research Program
$124,453Douglas B Johnson · Vanderbilt University Medical Center · P30 · FY2022 · CA
Translational Research and Interventional Oncology Research Program
$124,453Douglas B Johnson · Vanderbilt University Medical Center · P30 · FY2024 · CA
Translational Research and Interventional Oncology Research Program
$124,453Madan Jagasia · Vanderbilt University Medical Center · P30 · FY2021 · CA
Translational Research and Interventional Oncology Research Program
$124,453Madan Jagasia · Vanderbilt University Medical Center · P30 · FY2020 · CA
Translational Research and Interventional Oncology Research Program
$124,453Douglas B Johnson · Vanderbilt University Medical Center · P30 · FY2023 · CA
Cancer Center Support Grant
$124,398Douglas Yee · University Of Minnesota · P30 · FY2021 · CA
UW Comprehensive CANCER CENTER SUPPORT
$124,387Howard H Bailey · University Of Wisconsin-Madison · P30 · FY2021 · CA
NEUROPATHOLOGY/TISSUE BANK CORE
$124,188Claudia Katharina Petritsch · Stanford University · U54 · FY2023 · CA
[18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors
$124,109Shivaani Kummar · Oregon Health & Science University · R01 · FY2025 · CA
Targeting interplay between KLF4 and PRMT5 in carcinogenesis
$123,815Yong Wan · Northwestern University At Chicago · R01 · FY2018 · CA